An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

TODAY i have some great news to share. Besides the fact that last week was the King's Birthday, something exciting was happening in the HIV ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving innovations at risk.

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

Cost could make lenacapavir (Sunlenca; Gilead) inaccessible for people who would like to use it as a means of pre-exposure prophylaxis (PrEP) in the prevention of HIV, explained Gordon Crofoot, MD ...